Safety and Dosing Considerations for Clonazepam in Older Adults and REM‑Sleep‑Behavior Disorder

Dosing in REM‑Sleep‑Behavior Disorder (Secondary)

In patients with neurodegenerative disease who develop REM‑sleep‑behavior disorder, clinicians typically initiate clonazepam at a low dose of 0.25 mg to minimize sedation and motor side effects【1】.

The American Geriatrics Society Beers Criteria list clonazepam as a potentially inappropriate medication for older adults because of heightened risks of falls, sedation, and cognitive impairment【1】.
Age‑related declines in hepatic metabolism and baseline cognitive function often lead to gradual intolerance of clonazepam in elderly patients, necessitating very low starting doses and close monitoring【1】.
In older adults with neurodegenerative conditions, clonazepam can exacerbate sleep‑disordered breathing, increasing the risk of nocturnal hypoxia【1】.
Clinicians should be vigilant for morning sedation, gait instability, delirium, and amnesia when prescribing clonazepam to older patients, especially those with underlying neurodegenerative disease【1】.

Regular use of clonazepam carries a risk of tolerance, dependence, depression, and cognitive impairment, underscoring the need for careful indication selection and dose limitation【2】.
Approximately 10 % of patients may experience paradoxical agitation (e.g., increased restlessness or aggression) as an adverse reaction to clonazepam【2】.